Introduction {#S1}
============

A disintegrin and metaproteinase 10 (ADAM10) is member of a large group of human and non-human zinc-dependent enzymes (reviewed in [@B15]). Structurally it belongs to the adamalysin family ([Figure 1A](#F1){ref-type="fig"}, ADAM and ADAMTS enzymes). ADAM10 is a cell surface enzyme that sheds a wide variety of cell surface proteins ([@B26]; [@B47]; [@B13]; [@B90]) with importance in the progression of cancer, inflammation and immune response, suggesting that ADAM10 can be an important target for therapy.

![ADAM10 is a part of a large class of proteolytic enzymes. **(A)** ADAM family's place in metalloprotease hierarchy. Reproduced with permission from [@B15]. **(B)** ADAM10 domain organization. SS, signal sequence; Pro, prodomain; M, metalloproteinase; D, disintegrin; C, cysteine-rich; S, stalk region; TM, transmembrane; Cyt, cytoplasmic tail. (Adapted from [@B91]).](fmolb-07-00075-g001){#F1}

ADAM10 is comprised of several domains, namely signal sequence, prodomain, metalloproteinase domain, disintegrin domain, cysteine-rich domain, stalk region, transmembrane domain, and cytoplasmic tail ([Figure 1B](#F1){ref-type="fig"}), which are common for adamalysins ([@B97], [@B98]). ADAM10's most closely related adamalysin is ADAM17 with which it shares overall 24% amino acid sequence homology (as analyzed by Clustal Omega alignment tool). Despite low sequence homology ADAM10 and ADAM17 have a broadly overlapping and ever growing substrate repertoire, possibly due to the lack of well-defined cleavage site primary sequence specificity ([@B12]).

Functions of ADAM10 in any particular disease or normal physiological scenario are defined by the substrates that it cleaves; however, it is not well-known if ADAM10 and ADAM17 cleave the same substrates in the same setting. Therefore, inhibitors selective for ADAM10 can help differentiate its role in various scenarios.

Ability to cleave multiple substrates further complicates studies of ADAM10's role and, therefore, its validation as a target for any particular disease. ADAM10 cleaves receptors and receptor ligands such as cytokines, chemokines, cell adhesion molecules to name a few ([@B12]; [@B81]; [@B26]; [@B88]; [@B70]; [@B110]). An ADAM10 selective inhibitor that binds to a zinc of an active site will prevent proteolysis of all ADAM10 substrates. Given that ADAM10 substrates can counteract each other's biological effect (e.g., pro- and anti-inflammatory cytokines), a substrate-specific inhibitor of ADAM10 can be useful.

This notion lead to the deeper exploration of regulatory mechanisms governing recognition and interaction between ADAM10 and ADAM17 and their substrates by several groups, including ours. These studies led to the realization that ADAM10 and ADAM17 may have multiple levels or ways of regulation of substrate recognition and processing that are outside of their active sites. Among the regulatory mechanisms known so far are trafficking of ADAMs ([@B58]; [@B64]; [@B92]), interactions with other proteins ([@B46]), cellular membrane re-arrangement ([@B84]), ADAMs non-catalytic domains ([@B111]; [@B99]; [@B95]; [@B91]), topology of ADAM substrates ([@B95]), enzyme ([@B17]), and substrate glycosylation ([@B65]). As demonstrated by several groups these regulatory mechanisms can be targeted for a modulator discovery ([@B99]; [@B65]; [@B60]; [@B91]).

There has been a significant effort dedicated to the discovery of modulators of ADAM10 activity for multiple indications such as rhematoid arthritis (RA) ([@B72]), cancer ([@B73]; [@B20]; [@B89]), immune and neurodegenerative disorders ([@B110]). It is important to note, that for some indications (e.g., Alzheimer's disease) molecules that induce or potentiate ADAM10 activity are thought to be needed, whereas for the majority of other indications (e.g., cancer, inflammation) the inhibitors of activity are sought after.

There are several selective inhibitors of ADAM10 that are available to the researchers, including LT4 (ADAM10 IC~50~ = 40 nM, ADAM17 IC~50~ = 1500 nM; [@B120]), INCB8765 (Incyte Corporation, ADAM10 IC~50~ = 97 nM, ADAM17 IC~50~ = 2045 nM; [@B119]), GI 254023X (Glaxo, ADAM10 IC~50~ = 5.3 nM, ADAM17 IC~50~ = 541 nM; [@B59]), and ADAM10 prodomain (Biozyme Inc., ADAM10 IC~50~ = 48 nM, ADAM17 IC~50~ \> 10 μM; [@B71]). LT4, INCB8765 and GI254023X are small molecules containing hydroxamate moieties and, therefore, likely to inhibit ADAM10 *via* a Zn-binding mechanism ([@B115]) ([Figure 2](#F2){ref-type="fig"}). ADAM10 prodomain is a competitive inhibitor of ADAM10, but it is unknown whether it binds the active site Zn. While Zn-binding inhibitors can exhibit a degree of selectivity between closely related ADAM family members, they ultimately cannot selectively inhibit shedding of substrates. There is evidence that toxicity has been caused by off-target side effects ([@B22]; [@B75]; [@B69]) due to a Zn-binding mechanism of inhibition which results in broad spectrum inhibition of multiple Zn metalloproteases. Additionally, ADAM10 has been shown to cleave \> 70 cell surface proteins; therefore, indiscriminate inhibition of shedding of these proteins can affect multiple biological processes (reviewed in [@B26]; [@B110]).

![ADAM10 selective inhibitors. Zinc-binding moieties are in red circles. Modeling suggests bulky aromatic group (in the green circle) of LT4 interacts with S1' exosite of ADAM10. Bulky aromatic groups of INCB8765 and GI254023X potentially interacting with ADAM10 S1' site are in the blue circles. CID3117694 does not have apparent zinc-binding groups.](fmolb-07-00075-g002){#F2}

As shown by global knockout studies, ADAM10 ([@B38]) is vital for development, homeostasis and repair, which makes global inhibition of all functions of this enzyme non-feasible as a therapeutic approach. However, tissue-specific partial knockout studies of ADAM10 ([@B16]) demonstrated the lack of overall toxicity suggesting that local pharmacological partial inhibition of ADAM10 can be used.

Our group has discovered a new class of selective ADAM10 inhibitors that act *via* a non-Zn-binding mechanism ([@B60]) and potentially bind outside of an active site ([Figure 2](#F2){ref-type="fig"}). This non-Zn-binding mechanism of inhibition proved to be the key for ensuring selectivity of these molecules toward other Zn metalloproteinases. Additionally, the lead compound CID 3117694 from this new chemotype exhibits a unique *[substrate selectivity]{.ul}* profile ([@B60]) not observed with Zn-binding inhibitors of ADAM10, which should help avoid the off-target side effects described for Zn-binding inhibitors of ADAM10. For example, inhibition of shedding of amyloid precursor protein (APP) by ADAM10 ([@B28]) could lead to amyloid plaque formation in CNS. Additionally, many of Zn-binding inhibitors of metalloproteinases caused a dose-limiting toxicity known as Musculo-Skeletal Syndrome (MSS) ([@B77]).

Search of PubChem database for biological activity of CID 3117694 revealed that it was inactive in 524 bioassays and active only against 3 targets with ADAM10 being a top target (PubChem AID 743338). Second target was hERG -- CID 3117694 protected hERG from pro-arrhythmic agents (PubChem AID 1511, no EC~50~ value reported). Third target was DNA polymerase β (PubChem AID 485314) where CID3117694 exhibited IC~50~ value of 79 μM. It was inactive against adrenergic (ADRB2), muscarinic (CHRM1) and opioid receptors (OPRK1, OPRM1, and OPRD1) which are used for drug candidate safety screens ([@B9]). These data suggest that CID 3117694 is a non-promiscuous compound which should translate into low off-target *in vivo* toxicity. This also suggests that inhibition of ADAM10 *via* a non-Zn-binding mechanism could be an effective strategy for therapy with fewer side effects due to enzyme and substrate selectivity superior to Zn-binding inhibitors.

In the review presented herein we will discuss approaches and challenges of rational design and discovery of enzyme- and substrate-selective modulators of ADAM10.

Article {#S2}
=======

As mentioned above, there are multiple considerations and challenges in the development of small molecule therapy targeting ADAM10. Firstly, ADAM10 modulators need to be able to avoid affecting ADAM17 (and other metzincins) with which they share multiple common substrates ([@B12]). Additionally, since ADAM10 sheds multiple substrates, depending on the particular therapeutic indication, its modulators might need to be substrate-selective. ADAM17 selective inhibitors of ADAM10 have been reported ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). All ADAM10 substrates interact with a catalytic zinc atom of an ADAM10's active site, therefore, modulators acting *via* zinc-binding affect proteolysis of all ADAM10 substrates. All ADAM10 substrates interact with substrate secondary binding sites (exosites), however, it is conceivable that there are different sub-sets of substrates that interact with different exosites or sub-sets of exosites, which would determine a specificity of substrate-exosite interactions. Understanding which structural features of ADAM10 and its substrates determine and enable substrate-exosite interactions would then aid in the design of substrate-selective inhibitors.

###### 

Biochemical selectivity testing of ADAMs inhibitors against a panel of zinc metalloproteinases.

  **Compound**           **MMP1**   **MMP2**    **MMP8**   **MMP9**   **MMP14**   **ADAM10**   **ADAM17**
  ---------------------- ---------- ----------- ---------- ---------- ----------- ------------ ------------
  LT4^a^                 346        5.4         NT         24         100         **0.04**     1.5
  CID3117694^b^          \>100      \>100       \>100      \>100      \>100       **1.1**      \>100
  GI254023X^a^           0.125      0.0021^a^   NT         0.0051     0.088       **0.027**    0.86
  INCB8765^c^            \>5.0      \>5.0       NT         \>5.0      \>5.0       **0.097**    2.05
  ADAM10 pro-domain^d^   NT         NT          NT         NT         NT          **0.048**    \>10.0

Synthetic substrates were used for all assays. All results are IC
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What Is Known About ADAM10 Exosites? {#S2.SS1}
------------------------------------

To date there has been only one structural study of ADAM10 ectodomain ([@B91]) and only exosites that are described therein are in the catalytic domain. Comparison of the S1' site of ADAM10 and ADAM17 revealed that ADAM10 S1' site is deeper and more hydrophobic ([@B91]), which explains the previously reported preference for bulky hydrophobic residues ([@B12]). In a contrast, ADAM17 prefers smaller, non-aromatic hydrophobic residues ([@B12]; [@B100]).

Existing selective inhibitors of ADAM10 can provide additional insights into the ADAM10 secondary substrate binding sites. Differences in S1' pocket allowed the development ADAM10 selective inhibitor LT4 (referred to as compound **3** in [@B14]) (ADAM10 IC~50~ = 40 nM, ADAM17 IC~50~ = 1500 nM; [@B14]; [@B120]). Molecular homology modeling using ADAM17 crystal structure as a template suggested that the hydroxamate moiety coordinates zinc of an active site, while 4-(4-cyano-2-methylphenyl) piperazinyl group interacted with residues in the S1' tunnel.

To the best of our knowledge, there are no structural or modeling studies of interactions between ADAM10 and GI254023X, INCB8765 or ADAM10 ([@B71]). However, both GI254023X and INCB8765 have bulky aromatic groups ([Figure 2](#F2){ref-type="fig"}) that could be interacting with S1' exosite, which could explain their selectivity over ADAM17. Such a study of ADAM10 interactions with its pro-domain could also reveal additional previously undescribed exosites.

LT4, GI254023X, and INCB8765 are good examples of how the targeting of ADAM10 S1' exosite can result in metzincin-selective inhibitors. However, these ADAM10-selective compounds inhibit cleavage of all tested ADAM10 cognate substrates in the cellular models. For example, both LT4 and GI254023X prevented cleavage of activated leukocyte cell adhesion molecule (ALCAM), TNFα, MHC class I chain-related proteins A and B (MIC-A/B) and ULPBs (UL-16 binding proteins) from the surface of Hodgkin's lymphoma cells KMH2, L428, and L540 with a very similar potency ([@B14]). INCB8765 did not inhibit cleavage of ADAM17-ascribed substrates (heregulin, TGFα, HB-EGF and amphiregulin), but was not tested against a panel of ADAM10-specific substrates ([@B119]). LT4 and GI254023X testing of ADAM10 cellular substrates suggests that substrate-selective ADAM10 inhibition is difficult to achieve *via* targeting the combination of active site and S1' exosite. As an example of targeting beyond the active site, an ADAM10 selective inhibitor, CID3117694 ([Figure 2](#F2){ref-type="fig"}), inhibits ADAM10 *via* a non-zinc-binding competitive mechanism ([@B60]). It exhibits a preference for inhibition of TNFα-based glycosylated substrate ([Figure 3A](#F3){ref-type="fig"}) over its non-glycosylated variant ([Figures 3B,D](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}) whereas a zinc-binder marimastat inhibits proteolysis of both substrates equipotently ([Figure 3C](#F3){ref-type="fig"}). This substrate has a glycosylated Ser in the position P4' ([@B65]) suggesting that CID3117694 competes for the exosite occupied by the disaccharide of the glycosylated substrate, presumably in the vicinity of S4' exosite. The exact location and interacting residues in the structure of ADAM10 are not known. CID3117694 exhibits substrate selectivity as compared to GI254023X ([Table 2](#T2){ref-type="table"}). Most notably CID3117694 did not inhibit cleavage of HER2 and syndecan-4 when tested at 10 μM with BT474 and A549 cells, respectively, whereas GI254023X completely inhibited cleavage of both ADAM10 substrates.

###### 

Summary of testing of ADAM10 selective inhibitors with various cell-based ADAM10 and synthetic substrates.

  **Target**                 **Cell line**   **Glycosylation type**   **Position**                  **\[C\] tested, μM**   **CID3117694, %inhibition (IC~50~, μM)**   **GI254023X, %inhibition**
  -------------------------- --------------- ------------------------ ----------------------------- ---------------------- ------------------------------------------ ----------------------------
  TNFα non-glycosylated^a^   N/A             None                     N/A                           0.01--100              18 (\>100)                                 100
  TNFα glycosylated^a^       N/A             Gal-GalNAc               S^4^                          0.01--100              100 (1.1)                                  100
  HER2^a^                    BT474           GlcNAc                   Multiple ([@B118])            10                     0                                          100
  CXCL16^a^                  A549            Gal-GalNAc               Multiple ([@B1])              10                     80                                         100
  Syndecan-4^a^              A549            Heparan Sulfate          S^39^, S^61^, S^63^ ([@B7])   10                     0                                          100

NT, not tested.

a

Madoux et al. (2016)

.

![Glycosylated and non-glycosylated TNFa-based ADAM10 substrates are differentially inhibited by Zn-binding and non-Zn-binding inhibitors. Structures of **(A)** glycosylated and **(B)** non-glycosylated fluorogenic substrates. Fluorophore (Edans) and quencher (Dabcyl) are shown attached to glumatic acid (E) and lysine (K), respectively; **(C)** Proteolysis of both glycosylated and non-glycosylated substrates is inhibited equipotently by a Zn-binder marimastat, but not a non-Zn-binder CID3117694 **(D)**. Reproduced from [@B60] under Creative Commons License (<https://creativecommons.org/licenses/by/4.0/>).](fmolb-07-00075-g003){#F3}

The reason for substrate selectivity of CID3117694 is likely based on differences in glycosylation of ADAM10 substrates. CXCL16 is highly modified with mucin-like *O*-glycosylation containing galactose-*N*-acetylgalactosamine (Gal-GalNAc) as a part of its core structure within its stalk region where the cleavage by ADAM10 occurs ([@B1]). In contrast to CXCL16, syndecan-4 is *O*-glycosylated by heparan sulfate in three positions ([@B7]) and HER2 is *N*-glycosylated in seven positions 46--48. The substrate that was used to discover CID 3117694 is *O*-glycosylated with galactose-*N*-acetylgalactosamine (Gal-GalNAc) ([Figure 1A](#F1){ref-type="fig"}), which suggests that CID 3117694 inhibits CXCL16 shedding by preventing its binding to the Gal-GalNAc-binding exosite in ADAM10 structure. The lack of inhibition of syndecan-4 shedding by CID 3117694 is potentially due to the fact that it cannot compete with heparan sulfate moieties which are much larger than Gal-GalNAc. Weak inhibition of HER2 shedding could be explained by the size difference between *N*-acetylglucosamine (GlcNAc, monosaccharide) found on HER2 ([@B31]; [@B8]; [@B27]) and *N*-acetylgalactosamine (Gal-GalNAc, disaccharide) found on CXCL16. Another possible explanation is the distance of glycosylation site from the cleavage site. In case of the synthetic glycosylated substrate Gal-GalNAc is only four residues away from the cleavage site which is also likely the case with heavily *O*-glycosylated CXCL16, whereas in HER2 the most proximal to the cleavage site (^642^PAEQR∼ASP^650^) ([@B118]) glycosylation N^629^ is approximately 20 residues away.

Overall, ability of CID3117694 to differentiate between ADAM10 substrates based on their glycosylation status suggests that substrate glycosylation can be used as a target for drug discovery.

What Is Known About Glycosylation Status of ADAM10 Substrates and Its Effect on Proteolysis? {#S2.SS2}
--------------------------------------------------------------------------------------------

In order to be able to target an interaction between a glycan of an ADAM10 substrate and corresponding ADAM10 exosite it is necessary to know a position and type of glycan. Additionally, in order to avoid target-based toxicity, it is important that the target glycan is different in the specific diseased tissue vs. normal tissue. There are approximately hundred ADAM10 substrates ([@B26]; [@B110]) that have been described to date, however, their glycosylation status is largely unknown. Additionally, most of information about glycosylation of ADAM10 substrates is derived from studies of healthy tissues and little is known about glycosylation of the same proteins in various diseases.

IL6 receptor (IL-6R) has four *O*-glycosylated residues nearby the ADAM cleavage site TSLPVQ^357^∼DSSSV ([Table 3](#T3){ref-type="table"}) that could be modulating its proteolysis ([@B33]). Additionally, an N-linked glycan on Asn^55^ of the IL-6R 302 residues away from the cleavage site, was identified as a protease regulatory exosite, whose deletion caused increased shedding of the IL-6R ([@B86]). This suggests that even glycosylation far away from proteolytic site can be targeted for drug discovery. IL-6R was shown to be important in cancer ([@B23]; [@B40]; [@B109]; [@B116]) and RA ([@B2]) suggesting that ADAM10-mediated cleavage of IL-6R can be targeted for drug discovery for both indications. However, glycosylation profile of IL-6R in both cancer and RA is unknown.

###### 

Results of Pubmed and UniProt database searches for information on glycosylation of ADAM10 cognate substrates available for cancer and rheumatoid arthritis.

  **Accession \#**   **Substrate**          **Cleavage site**         **Known glycosylation position**                                                         **Closest distance from scissile bond, \#residues**   **Glyco type in normalcy**                                             **Role in cancer**                 **Glyco type in cancer**     **Role in RA**            **Glyco type in RA**
  ------------------ ---------------------- ------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------- ---------------------------- ------------------------- ----------------------
  P35070             Pro-betacellulin       CVVA^31^/^32^DGN\*S       N^34^                                                                                    3                                                     N-linked (GlcNAc) ([@B108]; [@B102])                                   [@B29]                             Not found                    [@B37]                    Not found
  P01375             pro-TNFa               LAQA^76^/^77^VRSS         S^80^                                                                                    4                                                     O-linked (GalNAc) ([@B33])                                             [@B45]; [@B42]; [@B66]; [@B61]     O-linked (GalNAc) ([@B96])   [@B43]                    Not found
  P02786             Transferrin receptor   TECER^100^∼ LAGT\*E       T^104^, N^251^, N^317^, N^727^                                                           4                                                     O-linked (GalNAc) ([@B24]; [@B39]; [@B53])                             [@B94]                             O-linked (GalNAc) ([@B87])   [@B78]                    Not found
  A0N0L5             IL6-R                  T\*SLPVQ^357^∼DS\*S\*SV   S^359^, S^360^, T^353^, N^55^, N^93^, N^221,^ N^350^                                     2                                                     O-linked (GalNAc) O-linked (HexNAc) N-linked (GlcNAc) [@B19]; [@B33]   [@B23]; [@B40]; [@B109]; [@B116]   Not found                    [@B2]                     Not found
  P05067             APP                    \*YEVHHQK^687^∼LVFFA      N^542^, N^571^, T^633^, T^651^, T^652^, S^656^, T^659^, T^663^, S^663^, S^667^, Y^681^   6                                                     N-linked (GlcNAc) ([@B34]; [@B11])                                     [@B112]; [@B113]                   Not found                    [@B49]                    Not found
  O14944             Pro-epiregulin         DNPR^59^/^60^VAQV         N^47^                                                                                    12                                                    N-linked (GlcNAc) ([@B103])                                            [@B107]                            Not found                    [@B37]                    Not found
  Q99075             pro-HB-EGF             RKVR^62^/^63^DLQE         T^37^, S^38^, T^44^, T^47^, T^75^, T^85^                                                 13                                                    O-linked (GalNAc) ([@B34], [@B35])                                     [@B10]; [@B32]; [@B68]; [@B30]     O-linked (GalNAc) [@B21]     [@B48]                    Not found
  P01135             pro-TGFa               VAAA^39^/^40^VVSH         N^25^                                                                                    14                                                    N-linked (GlcNAc) [@B104]                                              [@B117]; [@B80]                    Not found                    [@B36]                    Not found
  P04626             EGFR2                  AEQR^646^/^647^ASPL       N^68^, N^124^, N^187^, N^259^, N^530^, N^571^, N^629^                                    17                                                    N-linked (GlcNAc) ([@B31]; [@B8]; [@B27])                              [@B52]; [@B41]; [@B18]             Not found                    [@B36]; [@B93]            Not found
  P15514             pro-Amphiregulin       IVDD^100^/^101^SVRV;      N^30^, N^113^, N^119^                                                                    18                                                    N-linked (GlcNAc) ([@B105])                                            [@B76]; [@B85]                     Not found                    [@B74]; [@B114]; [@B57]   Not found
  P06734             CD23                   EERA^61^∼RN\*VSQVSKN      N^63^                                                                                    2                                                     N-linked (GlcNAc) [@B101]                                              [@B51]                             Not found                    [@B82]; [@B50]            Not found

Transferrin receptor (TfR) is shed by either ADAM10 or ADAM17 ([@B44]). *O*-linked carbohydrate four residues away from the scissile bond ([Table 3](#T3){ref-type="table"}) serves to protect the TfR from proteolytic cleavage, and without this protection, the TfR is more susceptible to cleavage ([@B87]). Soluble TfR (sTfR) is used as a diagnostic test for iron deficiency anemia in rheumatoid arthritis and other diseases ([@B78]; [@B6]). Concentration of sTfR and, therefore, the test results, depend on glycosylation status of TfR. It is conceivable that increase of sTfR in the serum of patients could be due to the change in the glycosylation of TfR. TfR importance in cancer and RA has been demonstrated ([@B78]; [@B94]), however, its glycosylation profile is known only for cancer ([@B87]).

Amyloid precursor protein (APP) has been studied mostly in the context of Alzheimer's disease (AD), however, recent reports show its importance in cancer ([@B112]; [@B113]) and RA ([@B49]). While APP is glycosylated in multiple positions ([@B34]), the closest residue to the ADAM cleavage site Y^681^EVHHQK^687^∼LVFFAED is Y^681^ ([Table 3](#T3){ref-type="table"}). Peptides with glycosylated Y^681^ were increased in CSF of AD patients (*n* = 6) versus non-AD patients ([@B113]) suggesting that this glycosylation could be specific to AD disease state. It is not known whether APP is glycosylated at Y^681^ in cancer and RA patients.

From [Table 3](#T3){ref-type="table"} it's quite clear that substrate- and disease-specific glycosylation data necessary to target each substrate need to be obtained in order to begin a rational design or discovery of ADAM10 substrate-selective inhibitors.

Lack of Structural Information Represents a Challenge in Using Glycosylation for Targeting {#S2.SS3}
------------------------------------------------------------------------------------------

In order to be able to target a specific glyco moiety on an ADAM10 substrate there needs to be a clear understanding of what this moiety is. It would be an understatement to say that protein glycosylation is complex. It is well known that glycosylation of the same protein may differ in normalcy vs. disease \[e.g., neurodegeneration ([@B67]), autoimmune disease ([@B54]), type 2 diabetes, inflammatory bowel disease, or colorectal cancer ([@B25])\]. Additionally, glycosylation may differ based on the stage of the disease ([@B83]), age and sex of the patient ([@B25]), type of disease etc. Therefore, as an example, information of glycosylation of target protein available for breast cancer should not be used for diabetes. To characterize a glyco moiety present on the specific target a significant amount of a protein is required, therefore, it needs to be either expressed or isolated from disease-specific cells. Recombinant proteins are typically produced in bacteria or insect cells due to higher yield. However, because glycosylation machinery is significantly different in humans this approach is not suitable for human disease-specific analysis. This suggests that a target protein needs to be isolated and characterized for glycosylation in the specific disease scenario using either patient cells or established cell lines. This presents a challenge given that microgram to milligram quantities of protein are needed for glycomic characterization and patient cells are usually a rare commodity.

Speculatively speaking, the expression profile of glycosylating/deglycosylating enzymes could be used as a possible alternative to the glycomic characterization of target proteins. Glycosylation of ADAM10 substrates depends on the repertoire of glycosylating/deglycosylating enzymes expressed in any particular disease and tissue. As an example, an expression profile of 210 glycosyltransferase (GT) genes from 1893 cancer patients correlated well with six cancer types ([@B3]). Also, it correlated with clinical classification of breast cancer sub-types.

As another example, increased levels of α-2,3-sialyltransferase-1 and neuraminidase-3 in monocytes of RA patients were found to correlate with disease activity score (DAS28) ([@B56]) resulting in increased sialylation. It stands to reason that GT expression profile is different in various tissues and disease states, therefore, knowledge of GT expression profile could help in identifying possible glycosylation changes in the disease state. It needs to be mentioned, however, that this approach has not been experimentally tested.

Are There Other Forms of ADAM10 Regulation Affecting Substrate Specificity? {#S2.SS4}
---------------------------------------------------------------------------

As mentioned in [@B91], disintegrin/cysteine-rich domain blocks access of protein substrates to the S1' and S2' pockets, resulting in auto-inhibition. Binding of 8C7 F~ab~ antibody to the disintegrin/cysteine-rich domain rendered ADAM10 active suggesting that disintegrin/cysteine-rich domain might contain an exosite (or exosites) which could be used by substrates to gain access to the active site. In the original report, 8C7 F~ab~ antibody was able to inhibit ADAM10-mediated ephrin cleavage, Eph activity and Eph-dependent cell behavior ([@B4]). This suggests that non-catalytic domains (NCDs) participate in substrate recognition and processing and, therefore, can be targeted for drug discovery.

Practical Considerations For Targeting Disease-Specific Glycosylation and Non-Catalytic Domains {#S3}
===============================================================================================

Drug discovery targeting exosites presents unique challenges. While established methodologies can be used, need to focus on previously unexplored target class introduces a new "twist" which, in some cases, may lead to an unsurmountable technical difficulty. Here we discuss how targeting glycosylation and NCDs affects applicability of established methods of drug discovery.

Compound Screening {#S3.SS1}
------------------

Once the type and position of glycosylation of target protein is known, the researchers needs to choose an assay format for a modulator discovery. Two main approaches to drug discovery are based on either purified target (i.e., biochemical assay) or target expressed in the cells of interest (i.e., cell-based assay). Depending on a therapeutic area, activators or inhibitors of ADAM10 activity might be needed. For example, for Alzheimer's disease the activators or potentiators of ADAM10 activity might be useful to increase non-amyloidogenic processing of APP thus decreasing amyloid plaque formation in CNS ([@B5]; [@B28]; [@B55]; [@B79]; [@B62]). Both biochemical and cell-based approaches have their inherent problems and advantages. Biochemical assays for ADAM10 modulators almost universally utilize synthetic fluorogenic substrates. These substrates need to be glycosylated using either chemical or chemoenzymatic approaches ([@B63]) that are not straightforward and expensive. The synthetic substrates are significantly shorter than the native ones and typically consist of 10--15 amino acid residues. This potentially results in the lack of interactions between such a substrate with non-catalytic domains (NCDs) of ADAM10. We previously reported an effect of NCDs of ADAM10 most closely related metzincin, ADAM17, on proteolysis of TNFα-based synthetic substrates. NCDs did not directly bind the substrates used in the study but affected the binding nevertheless, most likely because of steric hindrance ([@B95]). Additionally, fluorophore and quencher can interfere with binding of substrate to ADAM10. Finally, fluorogenic substrates are subject to fluorescent artifact ([@B63]) due to intrinsically fluorescent compounds present in high-throughput screening (HTS) libraries.

Conversely, cell-based assays are more pathophysiologically relevant than biochemical assays. The target protein is present in the native form containing all possible exosites in a more complex cellular environment. Since mostly immortalized cell lines are used for HTS as a proxy for a disease model, the presence of correct glycosylation form in the right position needs to be experimentally confirmed before utilizing a particular cell line. Detection of an ADAM10 activity modulation event in cell-based assays is another potential challenge. Detection of shedding of ADAM10 target is usually dependent on an antibody-based technology (e.g., western blot, ELISA, AlphaLISA). Western blot and ELISA are not amenable to HTS leaving only AlphaLISA (or its variation, AlphaScreen) as an enabling technology for the assay development. A main consideration with using AlphaLISA is an availability of an assay kit for a specific target. If a kit for the target of interest is not commercially available, then researchers can attempt to develop their own AlphaLISA assay using commercially available antibodies that will need to be conjugated to the AlphaLISA beads. The cell-based assay using AlphaLISA will need to be developed using "addition-only" format (i.e., no supernatant transferring) meaning that ADAM10 target will need to be detected in the supernatant in the presence of live cells. In our group we were able to develop and use such an assay to discover compounds increasing soluble APPα in the supernatant of live 7WD10 cells ([@B106]) suggesting feasibility of this approach.

Overall, the choice of the approach should be based on the availability of substrate structural information and technical resources, however, it needs to be mentioned that at this stage both are sorely lacking.

Computer-Aided Drug Design and Discovery {#S3.SS2}
----------------------------------------

Another approach to target glycosylation for ADAM10 modulator discovery can be based on virtual methods such as computer modeling and/or virtual screening. Either approach requires a pre-existing knowledge of an interaction site between a ligand and a target. In the case of ADAM10, such information is not available. This suggests a need for making a working virtual model by either docking a glycosylated substrate or other known exosite ligand (e.g., CID3117694). Once such a model is available, a medicinal chemist can use interactions between ADAM10 exosite and ligand revealed as a result of modeling effort to design a small molecule. Alternatively, a virtual screening can be performed using *de novo* model and publicly available virtual compound libraries (e.g., <https://zinc.docking.org>) to generate hits, which will need to be confirmed in ADAM10 assay.

Conclusion {#S4}
==========

Recent publications by different research groups independently demonstrated that glycosylation can affect ADAM10-mediated proteolysis. Research conducted in our group in the last 9 years has demonstrated that it is possible to target glycosylation of ADAM10 and ADAM17 for enzyme- and substrate-selective inhibitor discovery. This suggests that proteolysis of specific ADAM10 substrates involved in various diseases can be targeted using information about their glycosylation and non-catalytic domains differences.
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